Abstract:When SARS‐CoV‐2 enters inside the cell by fusion process it encodes few proteins including main protease with the help of cellular ribosomes. This main protease mediates the maturation cleavage of polyproteins at 11 different regions, which is a notable step in virus's life cycle. SARS‐CoV‐2 Mpro is mainly a homo‐dimeric enzyme consisting of three domains. The large substrate‐binding site with a catalytic dyad of His41 and Cys145 is located between chymotrypsin‐like domains I and picornavirus 3C protease‐like domain II. Inhibition of this substrate binding site disrupt the replication process. But being large substrate‐binding site, peptide is more suitable than small molecules for inhibiting this crucial site. The outcome of this computational study displays that the attachment of peptide with Mpro protease can be a good strategy to inhibit the substrate‐binding site which may lead to disruption of replication process of SARS CoV‐2. The COVID‐19 pandemic has been a public health emergency, with deadly forms constantly emerging around the world, highlighting the dire need for highly effective antiviral therapeutics. Peptide therapeutics show significant potential for this viral disease due to their efficiency, safety, and specificity. Here, two thousand seven hundred eight antibacterial peptides were screened computationally targeting the Main protease (Mpro) of SARS CoV‐2. Six top‐ranked peptides according to their binding scores, binding pose were investigated by molecular dynamics to explore the interaction and binding behavior of peptide‐Mpro complexes. The structural and energetic characteristics of Mpro‐DRAMP01760 and Mpro‐DRAMP01808 complexes fluctuated less during a 250 ns MD simulation. In addition, three peptides (DRAMP01760, DRAMP01808, and DRAMP01342) bind strongly to Mpro protein, according to the free energy landscape and principal component analysis. Peptide helicity and secondary structure analysis are in agreement with our findings. Interaction analysis of protein‐peptide complexes demonstrated that Mpro's residue CYS145, HIS41, PRO168, GLU166, GLN189, ASN142, MET49, and THR26 play significant contributions in peptide‐protein attachment. Binding free energy analysis (MM‐PBSA) demonstrated the energy profile of interacting residues of Mpro in peptide‐Mpro complexes. To summarize, the peptides DRAMP01808 and DRAMP01760 may be highly Mpro specific, resulting disruption in a viral replication and transcription. The results of this research are expected to assist future research toward the development of antiviral peptide‐based therapeutics for Covid‐19 treatment.

Characterization of SARS-COV-2 main protease inhibitory peptides from Ulva prolifera proteins

REVISITING THE SARS-COV-2 MAIN PROTEASE: A 2023 IN SILICO ODYSSEY IN SEARCH OF POTENTIAL INHIBITORS

Large scale peptide screening against main protease of SARS CoV‐2

Synthetic Peptides Outside the Spike Protein Heptad Repeat Regions As Potent Inhibitors of Sars-Associated Coronavirus

A Quick Route to Multiple Highly Potent SARS‐CoV‐2 Main Protease Inhibitors**

In Silico Study of Pacific oyster Antiviral Polypeptides as Potential Inhibitory Compounds for SARS-CoV-2 Main Protease

Design and evaluation of peptide inhibitors targeting the dimerization of SARS‐CoV‐2 main protease

SARS-CoV-2 M pro inhibitors with antiviral activity in a transgenic mouse model

The Identification of Peptide Inhibitors of the Coronavirus 3CL Protease from a Fucus ceranoides L. Hydroalcoholic Extract Using a Ligand-Fishing Strategy

Progress of SARS‐CoV‐2 Main Protease Peptide‐like Inhibitors

Isolation, Virtual Screening, and Evaluation of Hazelnut-Derived Immunoactive Peptides for the Inhibition of SARS-CoV-2 Main Protease

Marine natural compounds as potents inhibitors against the main protease of SARS-CoV-2—a molecular dynamic study

An ISG15-Based High-Throughput Screening Assay for Identification and Characterization of SARS-CoV-2 Inhibitors Targeting Papain-like Protease

Exploiting Hydrophobic Amino Acid Scanning to Develop Cyclic Peptide Inhibitors of the SARS‐CoV‐2 Main Protease with Antiviral Activity

Progress of SARS-CoV-2 Main protease peptide-like inhibitors

In silico screening of potential inhibitors from Cordyceps species against SARS-CoV-2 main protease

A Multi-Pronged Evaluation of Aldehyde-Based Tripeptidyl Main Protease Inhibitors As SARS-CoV-2 Antivirals

High-throughput Screening of SARS-CoV-2 Main and Papain-Like Protease Inhibitors

An in-silico evaluation of dietary components for structural inhibition of SARS-Cov-2 main protease

Discovery of potential inhibitors targeting SARS-CoV-2 Mpro

Discovery of a Highly Promising Disulfide Derivative Scaffold as Inhibitor of SARS-CoV-2 main protease